KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2016 - 2025)

Eli Lilly's EPS (Weighted Average and Diluted) history spans 14 years, with the latest figure at $7.39 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 51.43% year-over-year to $7.39; the TTM value through Dec 2025 reached $22.95, up 95.99%, while the annual FY2025 figure was $22.95, 95.99% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $7.39 in Q4 2025 per LLY's latest filing, up from $6.21 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $7.39 in Q4 2025 to a low of -$0.06 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.67, with a median of $2.02 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 103.73% in 2023, then soared 1883.33% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.89 in 2021, then rose by 13.23% to $2.14 in 2022, then rose by 13.08% to $2.42 in 2023, then soared by 101.65% to $4.88 in 2024, then surged by 51.43% to $7.39 in 2025.
  • Per Business Quant, the three most recent readings for LLY's EPS (Weighted Average and Diluted) are $7.39 (Q4 2025), $6.21 (Q3 2025), and $6.29 (Q2 2025).